EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies

Gyutae Choi iD, Sanghyo Lee iD, Seungjae Yoo, Jeung Tae Do iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178277 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Gyutae Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell and Regenerative Biotechnology, KU Institute of Technology, Konkuk University, Seoul 05029, Republic of Korea. Hauptthemen laut MEDLINE: Methyl-CpG-Binding Protein 2, Rett Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 265 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Konkuk University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rett syndrome is a severe neurodevelopmental disorder that occurs primarily in females and is caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene located on the X chromosome. Though MECP2 acts as a representative transcriptional regulator and affects gene expression both directly and indirectly, a complete understanding of this disease and the treatment mechanism has not been established yet. MECP2 plays a particularly important role in synaptic development, neuronal maturation, and epigenetic regulation in the brain. In this study, we summarize the molecular structure of MECP2, mutation-specific pathogenesis, and the role of MECP2 in regulating chromatin remodeling, RNA splicing, and miRNA processing to provide a comprehensive understanding of Rett syndrome. Additionally, we describe abnormal phenotypes manifested in various brain regions and other tissues owing to MECP2 dysfunction. Finally, we discuss current and future therapeutic approaches, including AAV-based gene therapy, RNA editing, X chromosome reactivation, and pharmacological interventions. Understanding the diverse functions and pathological mechanisms of MECP2 provides an important foundation for developing targeted therapies for Rett syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methyl-CpG-Binding Protein 2Rett SyndromeHumansAnimalsX ChromosomeCentral Nervous SystemMutationNeurotransmitter AgentsEpigenesis, Genetic

Stichwörter der Autor:innen

AAV gene therapyMECP2Rett syndromeX chromosome inactivationepigeneticsglial pathologyneuronal dysfunctiontranscriptional regulation

Substanzen

Methyl-CpG-Binding Protein 2Neurotransmitter Agents

Autor:innen und Institutionen

  • Department of Stem Cell and Regenerative Biotechnology, KU Institute of Technology, Konkuk University, Seoul 05029, Republic of Korea.
  • 3D Tissue Culture Research Center, Konkuk University, Seoul 05029, Republic of Korea.

ORCID-Profile: Gyutae Choi, Sanghyo Lee, Jeung Tae Do

Förderung

  • Konkuk University

Zitieren

APA

Choi, G., Lee, S., Yoo, S., & Do, J. T. (2025). MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178277

Vancouver

Choi G, Lee S, Yoo S, Do JT. MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178277

BibTeX
@article{Choi2025,
  author = {Choi, Gyutae and Lee, Sanghyo and Yoo, Seungjae and Do, Jeung Tae},
  title = {MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178277}
}
Kostenlos starten →